Abbott receives fda approval for minimally invasive portico™ with flexnav™ tavr system to treat patients with aortic valve disease

Abbott park, ill., sept. 20, 2021 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has approved the company's portico™ with flexnav™ transcatheter aortic valve replacement (tavr) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
ABT Ratings Summary
ABT Quant Ranking